(Hong Kong, 25 March 2021) Trustar Capital (formerly known as CITIC Capital Partners, a private equity
affiliate of CITIC Capital Holdings Limited) is pleased to announce that it has completed the subscription
of the convertible bonds issued by Genertec Universal Medical Group Company Limited (HKEX: 2666,
‘Genertec Universal Medical’ or ‘The Company’). The convertible bonds are issued in an aggregate
principal amount of USD150 million, with a 2% coupon and 5-year maturity.
The purposes of the net proceeds, which is equivalent to approximately USD148 million after expenses,
will be used to support the business development of the Company’s hospital group business, business
operation of its finance and advisory business, and general corporate purposes. Genertec Universal
Medical believes that the funding will further strengthen its strategic presence and leadership in the
healthcare industry.
The Company is an integrated healthcare service provider with focuses on the fast-growing healthcare
service industry in China. Leveraging its own rich medical resources and strong financial strength, the
Company strives to build up a trustworthy healthcare conglomerate focusing on medical services and
supported by financial services so as to gradually build a shared and win-win healthcare industrial
ecosystem. Currently, Genertec Universal Medical owns more than 50 hospital operations, with over
15,000 beds.
The Company strives to build up a trustworthy healthcare conglomerate by focusing on medical services
and supported by financial services and leverages on Trustar’s well-established track record of
investments into healthcare and financial services sectors in China and around the world, and its
accumulated extensive experience and resources.
Yichen ZHANG, Chairman of both CITIC Capital Holdings Limited and Genertec Universal Medical, said:
“Trustar and Genertec Universal Medical have fostered a solid long-term strategic partnership over the
years and we are delighted to have participated in their mixed ownership restructuring. We share their
business vision and are happy to help further improve the Company’s corporate governance, strategy
implementation, and capital market initiatives to facilitate its continuing growth and expansion in the
medical and financial services businesses.”
Ends –
About Genertec Universal Medical Group Limited
Genertec Universal Medical Group is a leading healthcare group in China and a listed subsidiary of
Fortune 500 company China General Technology (Group) Holding Co., Ltd, a backbone state-owned
enterprise under direct administration of the PRC central government. Focusing on China’s fast developing healthcare service sector and relying on the rich global healthcare resources and strong
capital strength, Genertec Universal Medical strives to build up a trustworthy healthcare conglomerate
focusing on medical services and supported by financial services so as to gradually build a shared and
win-win healthcare industrial ecosystem. For further information about the company and the relevant
announcement, please visit https://en.umcare.cn/.
About Trustar Capital
Trustar Capital (formerly known as CITIC Capital Partners), focuses on control buyout opportunities
globally and has completed over 80 investments since inception across China, Japan, U.S., Europe, etc.
Trustar Capital currently manages USD7.7 billion of committed capital. For more information, please visit
www.trustarcapital.com.
Trustar Capital is a private equity affiliate of CITIC Capital Holdings Limited. Founded in 2002, CITIC
Capital Holdings Limited is an alternative investment management and advisory company. The firm
manages over USD36 billion of capital across 90 funds and investment products through its multiple
asset class platform covering private equity, real estate, structured investment & finance, and asset
management. CITIC Capital has over 150 portfolio companies that span 11 sectors and employ over
800,000 people around the world.
For media enquiries, please contact:
Cindy TAM
Director, Corporate Relations
CITIC Capital Holdings Limited
Tel: +852 3710 6813
cindytam@citiccapital.com
Irene GAO
Senior Associate, Corporate Relations
CITIC Capital Holdings Limited
Tel: +852 3710 6814
irenegao@citiccapital.com
(Hong Kong, 17 March 2021) Trustar Capital (formerly known as CITIC Capital Partners), a private equity affiliate of CITIC Capital Holdings Limited, announced that it has completed its investment in Swiss-based global leading medical technology company MedAlliance SA (‘The Company’ or ‘MedAlliance’), becoming MedAlliance’s single largest shareholder. The investment will be used to fund the commercialization and roll-out of MedAlliance’s key product SELUTION SLRTM.
Headquartered in Nyon, Switzerland, MedAlliance is dedicated to developing and manufacturing of innovative drug-eluting balloons (DEBs) for patients suffering from life-threatening coronary and peripheral arterial disease. Using breakthrough proprietary technology, MedAlliance has found a unique solution to the challenge of controlled and sustained sirolimus release with SELUTION SLR TM. The unique technology has demonstrated impressive clinical trial results and is the first DEB company in the world to receive US Food and Drug Administration (FDA) Breakthrough Device Designation Status for a coronary DEB. Recently MedAlliance has received the fourth breakthrough designation award by FDA for its sirolimus DEB. MedAlliance’s technology is now available In Europe and other countries that recognize CE Mark and is in the process of completing FDA registration in the U.S.
Cardiovascular diseases (CVDs) are the number 1 cause of death globally. “Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019”, a report from J Am Coll Cardiol showed that total number of CVDs cases reached 523 million in 2019. According to a study published by the National Center for Cardiovascular Diseases in September 2020, there has been continued growth in the number of patients with cardiovascular disease in China. The demand for quality treatment and the development of newer technology related to coronary and peripheral diseases will continue to rise, especially in markets like China. MedAlliance has already commenced clinic trials of its core product SELUTION SLR TM in the Chinese market, and will continue to actively expand its footprints there.
“We are very pleased to have Trustar as a valued partner and to have established a strong relationship with their team over a substantial period of time. Their in-depth knowledge and expertise in the global medical device market will be of tremendous benefit to us”, said Jeffrey B. JUMP, Chairman and CEO of MedAlliance. “Validation from this highly successful and respected organization represents a significant endorsement of both our technology and our team and will help us to improve and extend the lives of patients around the world.”
Boon CHEW, Senior Managing Director and Managing Partner of Trustar Capital, said: “The global market size for medical devices addressing coronary and peripheral diseases has increased in recent years. In particular, we have seen exciting breakthroughs in technological development and clinical adoption in the interventional device space. MedAlliance has a very solid team of seasoned veterans with strong R&D capability and has successfully developed innovative products that lead the market in terms of technology and registration progress. We have been closely following MedAlliance for a considerable amount of time and have established a strong relationship with its management team. We are excited to be working together and will continue to bring good news to coronary and peripheral disease patients worldwide.”
Haiwen & Partners provided legal advice to Trustar Capital on the transaction.
– Ends –
About MedAlliance
Founded in 2008, MedAlliance is a privately-owned medical technology company. It is headquartered in Nyon (Switzerland), with facilities in Irvine (California), Glasgow (UK) and Singapore. MedAlliance specializes in the development of ground-breaking technology and commercialization of advanced drug device combination products for the treatment of coronary and peripheral artery diseases. For further information, please visit https://medalliance.com.
About Trustar Capital
Trustar Capital (formerly known as CITIC Capital Partners), focuses on control buyout opportunities globally and has completed over 79 investments since inception across China, Japan, U.S., Europe, etc. Trustar Capital currently manages USD7.6 billion of committed capital. For more information, please visit www.trustarcapital.com.
Trustar Capital is a private equity affiliate of CITIC Capital Holdings Limited. Founded in 2002, CITIC Capital Holdings Limited is an alternative investment management and advisory company. The firm manages over USD35 billion of capital across 90 funds and investment products through its multiple asset class platform covering private equity, real estate, structured investment & finance, and asset management. CITIC Capital has over 150 portfolio companies that span 11 sectors and employ over 800,000 people around the world.
For media enquiries, please contact:
Cindy TAM
Director, Corporate Relations
CITIC Capital Holdings Limited
Tel: +852 3710 6813
cindytam@citiccapital.com
Irene GAO
Senior Associate, Corporate Relations
CITIC Capital Holdings Limited
Tel: +852 3710 6814
irenegao@citiccapital.com